

Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information:

<http://www.tandfonline.com/loi/lncn20>

The Synthesis of [(β -d-Ribofuranosyloxy)-methyl]nucleosides

Dr. Hari Babu Mereyala^a & Sreeman Kumar Mamidyala^a

^a Gas Based Chemicals and Processes Division, Indian Institute of Chemical Technology, Tarnaka, Hyderabad, 500 007, India

Published online: 07 Feb 2007.

To cite this article: Dr. Hari Babu Mereyala & Sreeman Kumar Mamidyala (2004) The Synthesis of [(β -d-Ribofuranosyloxy)-methyl]nucleosides, Nucleosides, Nucleotides and Nucleic Acids, 23:4, 655-669, DOI: [10.1081/NCN-120030722](https://doi.org/10.1081/NCN-120030722)

To link to this article: <http://dx.doi.org/10.1081/NCN-120030722>

PLEASE SCROLL DOWN FOR ARTICLE

Taylor & Francis makes every effort to ensure the accuracy of all the information (the "Content") contained in the publications on our platform. However, Taylor & Francis, our agents, and our licensors make no representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content. Any opinions and views expressed in this publication are the opinions and views of the authors, and are not the views of or endorsed by Taylor & Francis. The accuracy of the Content should not be relied upon and should be independently verified with primary sources of information. Taylor and Francis shall not be liable for any losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever or howsoever caused arising directly or indirectly in connection with, in relation to or arising out of the use of the Content.

This article may be used for research, teaching, and private study purposes. Any substantial or systematic reproduction, redistribution, reselling, loan, sub-licensing, systematic supply, or distribution in any form to anyone is expressly forbidden. Terms & Conditions of access and use can be found at <http://www.tandfonline.com/page/terms-and-conditions>


The Synthesis of [(β -D-Ribofuranosyloxy)-methyl]nucleosides

Hari Babu Mereyala* and Sreeman Kumar Mamidyala

Gas Based Chemicals and Processes Division, Indian Institute of
Chemical Technology, Tarnaka, Hyderabad, India

ABSTRACT

The coupling reaction of acetoxymethoxy ribofuranoside **4** with nucleic acid bases **5a–f** to synthesize novel (ribofuranosyloxy)methyl uracil, thymine, cytosine, adenine, guanine derivatives **6a–g** respectively in preference to the expected formation of natural nucleosides 2',3',5'-tri-O-benzoyl uridine, methyluridine, cytidine, adenosine and guanosine **7a–g** is described. Detailed study of these reactions catalysed by Lewis acids TMSOTf and SnCl₄ is described. TMSOTf exhibited selectivity for the formation of ribofuranosyloxy methyl derivatives **6a–g** rather than **7a–g**. Reason for formation of **6a–g** is explained by HSAB principle.



Key Words: Acetoxymethoxy; Methyluridine; Cytidine; Adenosine; Guanosine.

*Correspondence: Dr. Hari Babu Mereyala, Deputy Director, Speciality, Gas Based Chemicals and Processes Division, Indian Institute of Chemical Technology, Tarnaka, Hyderabad 500 007, India; Fax: +91-040-716-0387 or +91-040-716-0757; E-mail: mereyalahb@rediffmail.com.


INTRODUCTION

The Vorbruggen^[1–7] modification of Hilbert–Johnson reaction^[8] of persilylated heterocyclic bases with peracylated sugars in presence of Friedel–Crafts catalysts has become a standard synthetic method for preparation of natural nucleosides routinely in high yields. The reaction of silylated pyrimidines and purines with 1-*O*-acetyl-2,3,5-tri-*O*-benzoyl- β -D-ribofuranoside is known to proceed via a stable electrophilic 1,2- α -acyloxonium intermediate.^[9–13] The various mechanisms of all these synthetic methods of nucleoside synthesis have been earlier studied, carefully reviewed^[14,15] and discussed.^[16]

In this report we describe our experiments aimed at the concept of fine-tuning the acetoxymethoxyglycosyl derivative **a** to generate glycosyloxy carbocation **b** and capture it by nucleic acid bases **B** to achieve synthesis of novel glycosyloxymethyl nucleosides **d** (Scheme 1). Glycosyloxy carbocation **b** has a tendency to fragment further to the thermodynamically more stable ‘glycosyl cation **c**’ and form the natural nucleoside **e** when captured by **B**. The results of this fundamentally new approach might have some significance in developing newer themes in carbohydrate chemistry.^[17–20]


The key acetoxymethoxy substrate **a** required to illustrate the above concept was elegantly synthesized from 1-*O*-acetyl-2,3,5-tri-*O*-benzoyl- α / β -D-ribofuranoside (**1**)^[21,22] by initial reaction with propargyl alcohol, $\text{BF}_3 \cdot \text{Et}_2\text{O}$ in CHCl_3 at room temperature to isolate propynyl ribofuranoside derivative **2**^[23] (Scheme 2). Compound **2** on further reaction with a catalytic amount of $\text{Hg}(\text{OCOCF}_3)_2$ in acetone- H_2O (2:1) at room temperature gave the corresponding keto derivative **3**. Baeyer–Villiger oxidation of keto compound **3** with *m*-CPBA in CHCl_3 gave 1-[(2,3,5-tri-*O*-benzoyl- β -D-ribofuranosyloxy)methyl]acetate (**4**) as a crystalline solid, mp 71°C in 42% overall yield starting from **1**.^[24] Compound **4** was characterized by ^1H NMR (the methylene protons at δ 5.36, δ 5.42 as an AB type quartet, $J = 7.5$ Hz and H-1 at δ 5.56 as a singlet) and ^{13}C NMR (the methylene carbon at δ 84.7 and C-1 at δ 103.9).

In order to study the potential of the envisaged concept a Vorbruggen modified Hilbert–Johnson reaction of **4** with *bis*(trimethylsilyl) uracil (**5a**), *bis*(trimethylsilyl)-thymine (**5b**) and *bis*(trimethylsilyl) cytosine (**5c**)^[25] was affected (Scheme 3) with the Friedel–Crafts catalyst $\text{Sn}(\text{IV})\text{Cl}/\text{CHCl}_3$ at room temperature for 4–6 h. It resulted in the formation of a mixture of ribofuranosyloxymethyl uracil **6a**, -thymine **6b**, -cytosine **6c** derivatives (24–30% yield) along with the corresponding natural nucleosides



Scheme 1. Mechanism proposed for the formation of [(β -D-ribofuranosyloxy)methyl]nucleosides.






Scheme 2. Synthesis of acetoxymethoxy ribofuranoside **4**.

2',3',5'-tri-*O*-benzoyluridine, 5-methyluridine, and cytidine (**7a–c** respectively, 45–47% yield) (Table 1, entries i,iii,v).

The mixture of ribofuranosyl derivatives **6a–c** and **7a–c** was separated by column chromatography and characterized by ¹H NMR spectra as 1-[2,3,5-tri-*O*-benzoyl- β -D-ribofuranosyloxy)methyl]uracil (**6a**), 1-[(2,3,5-tri-*O*-benzoyl- β -D-ribofuranosyloxy)methyl]thymine (**6b**), 1-[(2,3,5-tri-*O*-benzoyl- β -D-ribofuranosyloxy)methyl]cytosine (**6c**) respectively (the methylene protons at δ 5.10–5.15 (1 H) and δ 5.36–5.40 (1 H) as an AB type quartet, J = 10 Hz and H-1' at δ 5.50–5.60 as a singlet) and ¹³C NMR (the methylene carbon at δ 78.0–80.0 and C-1 at δ 104.2–104.7). Unambiguous assignment of structure for **6a–c** was accomplished after hydrolysis (NaHCO₃/MeOH) to isolate **8a–c** respectively, characterized (Scheme 3) as 1-[(- β -D-ribofuranosyloxy)methyl]uracil (**8a**), 1-[(- β -D-ribofuranosyloxy)methyl]thymine (**8b**) and 1-[(- β -D-ribofuranosyloxy)methyl]cytosine (**8c**) respectively by ¹H NMR (the methylene protons at δ 5.20–5.27 (1 H) and δ 5.35–5.40 (1 H) as an AB type quartet J = 10 Hz and H-1' at δ 5.20–5.22 as a singlet) and ¹³C NMR (the methylene carbon at δ 82.5–83.5 and C-1' at δ 105.2–106.0).

The differentiation of N-1 alkylation from N-3 of **8a–c** was readily accomplished by comparison of ultraviolet spectra of the compounds in neutral vs 0.1 N alkali.^[26–28] They were characterized as N-1alkylation products as they showed less than a 2-m μ shift. Natural nucleosides **7a–c** were characterized as 2',3',5'-tri-*O*-benzoyluridine (**7a**), 5-methyluridine (**7b**) and cytidine (**7c**) respectively (Scheme 3) by comparison of their ¹H NMR spectral data and melting point with those reported in literature.^[29] Formation of compounds **6a–c** and **7a–c** can be explained from the capture of oxymethyl carbocation **b** and ribofuranosyl cation **c** respectively by the base **B** (**a–c**) (Scheme 1). In order to drive the reaction towards the formation of **6** alone, we have studied the replacement of SnCl₄ by the weaker Friedel–Crafts catalyst (CH₃)₃SiOSO₃CF₃ (TMSOTf) to perform the coupling reaction.^[30] Thus, reaction of **4** with **5a** (entry ii) and **5b** (entry iv) was carried out with TMSOTf/CHCl₃ at reflux temperature (3–5 h) to isolate **6a** and **6b** respectively in high yield, and formation of **7a** and **7b** was not observed (Table 1). The generality of the reaction was studied for coupling of **4** with cytosine derivative **5c** under similar reaction conditions, resulting in the isolation of **6c** and **7c** in a ratio of 1:1 respectively (Table 1, entry vi) indicating moderate selectivity,





Scheme 3. Synthesis of [(β-D-ribofuranosyloxy)methyl]nucleosides.

probably due to the higher basicity of cytosine.^[31,32] In order to achieve the selective formation of **6c**, coupling of **4** with *bis*(trimethylsilyl)-*N*⁴-benzoylcytosine (**5d**)^[33] was attempted, resulting in the isolation of *N*⁴-benzoyl-1-[(2,3,5-tri-*O*-benzoyl-β-D-ribofuranosyloxy)methyl]cytosine (**6d**) and *N*⁴-2,3,5-tetra-*O*-benzoyl cytidine (**7d**) in a ratio of 3:1 respectively (entry vii). Thus, use of the *N*⁴-benzoyl derivative of cytosine in the coupling reaction has resulted in the isolation of the desired product **6d** in higher yield. In order to establish the generality of the reaction, coupling of **1** with *bis*(trimethylsilyl)-*N*⁶-benzoyladenine (**5e**)^[34] was carried out in SnCl₄/MeCN at room temperature to isolate **6e** and **7e** respectively, in a ratio of 1:2 (entry viii) (Scheme 3). A similar observation was made in the coupling of **4** with **5a–c**. Compound **6e** was characterized analogously to **6a–c**. In order to assign the regiochemistry, **6e** was hydrolyzed (NaHCO₃/methanol) to 9-[(β-D-ribofuranosyloxy)methyl]adenine (**8e**) and characterized by an ¹H NMR spectrum analogous to natural nucleosides from the appearance of H-2 and H-8 protons at δ 8.25 and δ 8.20, respectively, indicating it to be the *N*⁹ isomer.^[35] Natural nucleoside **7e** was characterized as *N*⁶,2,3,5-tetra-*O*-benzoyladenine (**7e**) by comparison of its ¹H NMR spectrum, melting point and optical rotation with that reported in literature^[29] and was found to be the *N*⁹ regioisomer. In order to enhance the formation of **6e**, coupling of **4** with **5e** was studied



Table 1. Coupling of **4** with nucleic acid bases **5a–f**.

Entry	Solvent	Temperature	Catalyst	Reaction time (h)	6a–f , 5ff (% yield)	7a–f , 6ff	Ratio of 6f (%yield)
i	a	RT	A	5	6a (30.6)	7a (46)	1.0:1.5
ii	a	reflux	B	3	6a (98.1)	7a (0)	1.0:0.0
iii	a	RT	A	4	6b (28.0)	7b (45.2)	1.0:1.6
iv	a	reflux	B	4	6b (78.5)	7b (0)	1.0:0.0
v	a	RT	A	6	6c (29.5)	7c (47.3)	1.0:1.6
vi	a	reflux	B	6	6c (36.5)	7c (36.5)	1.0:1.0
vii	a	reflux	B	4	6d (52.0)	7d (17.0)	3.0:1.0
viii	b	RT	A	16	6e (20.6)	7e (39.6)	1.0:1.9
ix	b	RT	B	16	6e (45.4)	7e (34.9)	1.3:1.0
x	b	reflux	B	2	6e (30.2)	7e (32.0)	1.0:1.0
xi	a	RT	B	16	no reaction	–	–
xii	a	reflux	B	2	decomposition	–	–
xiii	b	RT	A	18	6f : 6g (17.4) N ⁹ : N ⁷ = 1:12.2	7f : 7g (27.8) N ⁹ : N ⁷ = 1:7.2	1.0:1.6
xiv	b	reflux	A	1	6f : 6g (10.2) N ⁹ : N ⁷ = 1:2.4	7f : 7g (79.6) N ⁹ : N ⁷ = 1.7:1.0	1.0:7.8
xv	b	RT	B	17	6f : 6g (22.7) N ⁹ : N ⁷ = 1.1:1.0	7f : 7g (61.3) N ⁹ : N ⁷ = 1.0:1.6	1.0:2.7
xvi	b	reflux	B	3	6f : 6g (21.3) N ⁹ : N ⁷ = 1.2:1.0	7f : 7g (38.3) N ⁹ : N ⁷ = 1.4:1.0	1.0:1.8
xvii	c	reflux	B	2	6f : 6g (57.0) N ⁹ : N ⁷ = 1.1:1.0	7f (0)	1.0:0

a = CHCl₃; b = CH₃CN; c = 1,2-Dichloroethane; A = Sn(IV)Cl₄; B = TMSOTf.

by use of a weaker catalyst (TMSOTf) in solvents such as CHCl_3 (entry xi, xii) and MeCN (entry ix, x) at room temperature to reflux temperature. The best result was the formation of a mixture of **6e** and **7e** respectively (Table 1), in a ratio 1.3:1 in MeCN at room temperature (entry ix). The observed moderate selectivity in this reaction needs to be studied in detail. The scope and utility of the coupling reaction was also examined for the preparation of ribofuranosyloxymethyl guanine derivatives in view of their importance as pharmacologically active compounds such as acyclovir,^[36,37] ganciclovir^[38,39] and penciclovir.^[40] Coupling of **4** and *N*²-acetyl-*tris*(trimethylsilyl)-guanine (**5f**)^[41] in $\text{SnCl}_4/\text{MeCN}$ at room temperature gave **6f,6g:7f,7g** (a ratio of 1:1.6, entry xiii) while at reflux temperature coupling resulted in the formation of the undesired nucleosides in larger amount (a ratio of 1:7.8, entry xiv). Reactions by change of solvent and catalyst was attempted to enhance the selective formation of **6f,6g**. Thus, coupling of **4** with **5f** in TMSOTf/MeCN at room temperature gave **6f,6g:7f,7g** in a ratio of 1:2.7 (entry xv), and at reflux temperature it changed to 1:1.8 (entry xvi). The change of solvent to 1,2-dichloroethane and reaction at reflux temperature has exhibited the desired selectivity and resulted in the formation of **6f,6g** in 57% isolated yield (entry xvii), while formation of **7f,7g** was not observed. TMSOTf was found to be the suitable catalyst for preparation of ribofuranosyloxymethyl derivatives **6a–g**. Compounds **6f,6g** and **7f,7g** were found to be a mixture of *N*⁹/*N*⁷ regioisomers, **6f,6g** were characterized analogously to **6a–c**. In order to assign the regiochemistry^[42–44] **6f,6g** were hydrolyzed to **8f,8g** respectively (Scheme 3) and unambiguously characterized^[42–44] by the ¹H and ¹³C NMR as 9-[-(β-D-ribofuranosyloxy)methyl] guanine (**8f**) (the H-8 at δ 7.75 as a singlet, NH₂ at δ 6.55; C-5 at δ 116.4, C-8 at δ 137.7 and C-4 at δ 151.2) and 7-[-(β-D-ribofuranosyloxy)methyl]guanine (**8g**) (the H-8 at δ 8.0 as singlet, NH₂ at δ 6.20; C-5 at δ 105.7, C-8 at δ 145.0 and C-4 at δ 161.0) respectively.^[42–44] *N*²-Acetyl-9-(2,3,5-tri-*O*-benzoyl-β-D-ribofuranosyl)guanine (**7f**) and *N*²-acetyl-7-(2,3,5-tri-*O*-benzoyl-β-D-ribofuranosyl) guanine (**7g**) were characterized as *N*⁹ and *N*⁷ linked natural nucleosides respectively by comparison of their ¹H NMR spectra and melting point with that reported in literature.^[29,42–44]

Formation of regioisomers *N*⁹ (**6f** and **7f**) and *N*⁷ (**6g** and **7g**) was studied by change of solvent (MeCN, 1,2-dichloroethane), temperature (room temperature, reflux) and catalyst (Sn(IV)Cl_4 , TMSOTf). From these experiments it was observed that in the formation of regioisomers **6f,6g** and **7f,7g** respectively, the *N*⁷ isomer predominated over *N*⁹ in SnCl_4 under kinetically controlled conditions, where as under thermodynamic conditions no such selectivity was observed in SnCl_4 or TMSOTf. The lack of regioselectivity observed in the present study is ascribed to the difference in reactivity of donors **4** and **1**, bearing the acetoxymethoxy and the acetyl leaving group respectively. Attempted isomerisation^[35,45] of *N*⁷ isomer **6g** in TMSOTf/MeCN at reflux temperature resulted in the decomposition, and formation of **6f** (*N*⁹ isomer) or natural nucleosides **7f** and **7g** was not observed.

We have earlier reported^[24] that acetoxymethoxy glycopyranosides **a** couple with alcohols (sugar and simple alcohols) to form *O*-glycosides due to the capture of glycosyl cation **c**, while formation of products resulting from the capture of glycosyloxymethyl carbocation **b** was not observed. In the present study we have shown that coupling with nitrogen bases lead to the formation of products by capture of intermediate **b** in preference to **c**. The reason for selectivity appears to be according to the HSAB principle.^[46–48] The glycosyl cation **c** is a hard acid and couples with hard



bases^[31,32,49] (alcohols, cytosine and adenine), where as carbocation **b** is a borderline soft acid and is captured by soft base^[31,32,49] (uracil, thymine and guanine).

In summary synthesis of novel ribofuranosyloxymethyl uracil, thymine, cytosine, adenine and guanine was achieved by fine tuning of the acetoxymethoxy leaving group of ribofuranoside. Application of this method for the synthesis of other glycosyl derivatives is under investigation.

EXPERIMENTAL

¹H NMR spectra were recorded using the following instruments: at 200 MHz on a Varian Gemini, at 300 MHz on a Bruker Avance; at 400 MHz on a Varian Unity; at 500 MHz on a Varian Inova, with tetramethyl silane as internal standard for solutions in deuteriochloroform. *J* values are given Hz. ¹³C NMR spectra were taken with Varian Gemini (50 MHz), Bruker Avance (75 MHz) spectrometer with CDCl₃ as internal standard (C 77.0) for solutions in deuteriochloroform, DMSO-d₆ (C 39.7) for solutions in deuterio dimethyl sulfoxide, dioxane (C 67.3) for solutions in deuterated water. Optical rotations were measured with a JASCO DIP-370 instrument. Melting points were determined by using Fischer–John’s melting point apparatus and are uncorrected. IR spectra were taken with a Perkin–Elmer 1310 spectrometer. UV spectra were recorded on a Shimadzu UV 160A spectrometer. Organic solutions were dried over anhydrous Na₂SO₄.

A Typical Procedure for Coupling of Ribofuranoside Derivative 4 with Nucleic Acid Bases 5a–f (Method A: SnCl₄ or Method B: Trimethylsilyltrifluoromethane sulfonate (TMSOTf) (1.2–2.0 mmol, 0.5N in CHCl₃ or MeCN or 1,2-dichloroethane). To a solution (20 ml) of ribofuranoside derivative **4** (1.0 mmol) and silylated nucleic acid bases **5a–f** (1.2 mmol) at 0°C was added the catalyst under nitrogen atmosphere. The reaction mixture was stirred at room temperature for 4–18 h or reflux temperature for 1–6 h, progress of the reaction was monitored by TLC. After completion of the reaction it was neutralized with saturated aqueous NaHCO₃ solution and filtered through a celite pad. The filtrate was extracted into CHCl₃ (30 ml), organic phase was separated, washed with brine, dried over anhydrous Na₂SO₄ and the solvent was removed under reduced pressure to obtain a residue. The residue was separated by column chromatography [SiO₂, 60–120 mesh, ethyl acetate:chloroform] to isolate the title compounds **6a–g** and **7a–g**.

2-Propynyl 2,3,5-Tri-*O*-benzoyl- β -D-ribofuranoside (2). To a solution of 1-*O*-acetyl-2,3,5-tri-*O*-benzoyl- α/β -D-ribofuranoside (**1**) (20.0g, 39.7 mmol) in dry CHCl₃ (200 mL) was added propargyl alcohol (2.8 mL, 47.6 mmol) and BF₃·Et₂O (6 mL, 47.6 mmol) at 0°C. The reaction mixture was stirred at room temperature for 5 h. After completion of the reaction, anhydrous K₂CO₃ (6.0 g) was added, stirred for further 30 min., filtered, and the residue was washed with CHCl₃ (50 mL). The filtrate was transferred to a separating funnel, washed with water (100 mL \times 2) and brine (100 mL). The organic phase was separated, dried (Na₂SO₄) and concentrated to obtain a residue. The residue was chromatographed [SiO₂; hexane–ethyl acetate (9:1)] to isolate the *title compound 2* (13.3 g,



68%) as a crystalline solid. mp 56°C; $[\alpha]_D$ 12.4 (c 1.0, CHCl₃); IR (KBr) ν_{\max} 3277, 3238, 2954, 2884, 2108, 1731, 1717, 1604, 1485, 1392, 1261, 1170, 1123, 1093, 1031 and 954 cm⁻¹; ¹H NMR (200 MHz; CDCl₃) δ 2.41 (1H, t, C \equiv CH), 4.25, 4.35 (2H, AB quartet, J = 9.3 Hz, CH₂–C \equiv C), 4.52 (1H, dd, J = 13.0, 6.0 Hz, H5), 4.60–4.80 (2H, m, 4H, H5'), 5.48 (1H, s, H1), 5.72 (1H d, J = 4.6 Hz, H2), 5.90 (1H dd, J = 3.7 Hz, H3), 7.25–8.25 (15H, m, aromatic); ¹³C NMR (50 MHz; CDCl₃) δ 54.5 (HC \equiv C–), 64.5 (C5), 72.1 (C4), 75.7 (C3), 75.9 (O–CH₂–C), 78.3 (HC \equiv C–), 79.4 (C2), 103.4 (C1), 128–135 (aromatic), 165.03, 165.77 and 166.06 (C=O, ester); FAB-MS m/z : 523 [M⁺ + Na]; Anal. Calcd for C₂₉H₂₄O₈: C, 69.59; H, 4.83. Found: C, 69.42; H, 4.78.

2-(Oxopropoxy) 2,3,5-Tri-*O*-benzoyl- β -D-ribofuranoside (3). To a solution of 2-propynyl 2,3,5-tri-*O*-benzoyl- β -D-ribofuranoside (**2**) (13.0 g, 26 mmol) in acetone: H₂O (200 mL, 2:1) was added Hg(OCOFCF₃)₂ (2.21 g, 5.18 mmol). The reaction mixture was stirred at room temperature for 6h. After completion of the reaction, acetone was evaporated, the resulting residue was dissolved in ethyl acetate (200 mL), washed with 10% aqueous KI solution (100 mL \times 2), 20% aqueous hypo solution (100 mL \times 2) and brine (100 mL). The organic layer was separated, dried over Na₂SO₄ and concentrated to obtain the *title compound* **3** (12.9 g, 96%) as a solid. mp 75°C; $[\alpha]_D$ 3.1 (c 1.0, CHCl₃); IR (KBr) ν_{\max} 2977, 2953, 2885, 2870, 2830, 1731, 1715, 1584, 1446, 1308, 1262, 1108, 1046, 1015 and 708 cm⁻¹; ¹H NMR (200 MHz; CDCl₃) δ 2.10 (3H, s, CH₃), 4.10, 4.24 (2H, AB type quartet, J = 10.0 Hz, OCH₂C), 4.52 (1H, dd, J = 13.0, 6.0 Hz, H5), 4.60–4.80 (2H, m, H4, H5'), 5.30 (1H, s, H1), 5.80 (1H, d, J = 4.7 Hz, H2), 5.90 (1H, dd, J = 3.7 Hz, H3), 7.20–8.25 (15H, m, aromatic); ¹³C NMR (50 MHz; CDCl₃) δ 26.3 (CH₃), 64.3 (C5), 71.9 (C4), 72.3 (OCH₂C), 75.3 (C3), 79.5 (C2), 105.1 (C1), 125–135 (aromatic), 165.0, 165.2 and 165.1; (C=O, ester); FAB-MS m/z : 541 [M⁺ + Na]; Anal. calcd for C₂₉H₂₆O₉: C, 67.17; H, 5.05. Found: C, 67.37; H, 5.18.

1-[(2,3,5-Tri-*O*-benzoyl- β -D-ribofuranosyloxy)methyl]acetate (4). To a solution of 2-(oxopropoxy)2,3,5-tri-*O*-benzoyl- β -D-ribofuranoside (**3**) (12.0g, 23.2 mmol) in dry CHCl₃ (120 mL) was added *m*-CPBA (9.6 g, 55.6 mmol). The reaction mixture was stirred at room temperature for 12h. After completion of the reaction, the reaction mixture was diluted with CHCl₃ (150 mL), washed with saturated aqueous NaHCO₃ solution (150 mL \times 3, water (150 mL), brine (150 mL) and dried (Na₂SO₄). The solvent was concentrated to give a residue which was purified by silica gel chromatography (SiO₂, hexane:ethyl acetate, 9:1) to obtain the *title compound* **4** as a white solid. mp 71°C; $[\alpha]_D$ 8.0 (c 1.0, CHCl₃); UV λ_{\max} (MeOH) nm: 274; IR (KBr) ν_{\max} 3062, 3015, 2938, 1752, 1731, 1604, 1430, 1261, 1107, 1046, 1015 and 708 cm⁻¹; ¹H NMR (200 MHz; CDCl₃) δ 2.10 (3H, s, CH₃), 4.54 (1H, dd, J = 13.0, 4.65 Hz, H5), 4.66–4.86 (2H, m, H4, H5'), 5.36, 5.42 (2H, AB type quartet, J = 7.5 Hz, OCH₂O), 5.56 (1H, s, H1), 5.75 (1H, d, J = 6.5 Hz, H2), 5.90 (1H, dd, J = 4.4 Hz, H3), 7.20–8.20 (15H, m, aromatic); ¹³C NMR (50 MHz; CDCl₃) δ 20.8 (CH₃) 64.4 (C5), 71.9 (C4), 75.4 (C3), 79.5 (C2), 84.7 (OCH₂O), 103.9 (C1), 125–135 (aromatic), 165.0, 165.2 and 170.1 (C=O, ester); FAB-MS m/z : 535 [M⁺ + H]; Anal. calcd for C₂₉H₂₆O₁₀: C, 65.16; H, 4.90. Found: C, 65.27; H, 5.11.

1-[(2,3,5-Tri-*O*-benzoyl- β -D-ribofuranosyloxy)methyl]uracil (6a). Prepared according to method B (2.24 mmol) by reacting **4** (1.0 g, 1.87 mmol) and **5a** (0.57 g,

2.24 mmol) in CHCl_3 (40 mL) at reflux for 3 h to isolate the title compound as a pale yellow solid (1.07 g, 98.1% yield). mp 78–80°C; $[\alpha]_D$ 16.0 (c 1.0, CHCl_3); UV λ_{max} (MeCN) nm: 259; IR (KBr) ν_{max} 3062, 2107, 1723, 1677, 1446, 1262, 1154, 1086, 1015, 816 and 692 cm^{-1} ; ^1H NMR (200 MHz; CDCl_3) δ 4.60 (1H, dd, $J = 13.0, 5.5$ Hz, H5'), 4.60–4.80 (2H, m, H4', H5''), 5.14, 5.38 (2H, AB type quartet, $J = 10.0$ Hz, OCH_2N), 5.50 (1H, s, H1'), 5.62 (1H, d, $J = 5.6$ Hz, H2'), 5.65 (1H, d, $J = 5.5$ Hz, H5), 5.82 (1H, dd, $J = 4.0$ Hz, H3'), 7.18 (1H, d, H6), 7.20–8.20 (15H, m, aromatic), 9.0 (1H, br s, NH); ^{13}C NMR (50 MHz; CDCl_3) δ 64.3 (C5'), 71.7 (C4'), 74.5 (C3'), 75.5 (C2'), 78.0 (OCH_2N), 103.0 (C5), 104.5 (C1'), 127–135 (aromatic), 143.5 (C6), 150.0 (C=O, C2), 163.5 (C=O, C4), 165.0, 165.3 and 166.0 (C=O, ester); FAB-MS m/z : 609 $[\text{M}^+ + \text{Na}]$; Anal. calcd for $\text{C}_{31}\text{H}_{26}\text{O}_{10}\text{N}_2$: C, 63.48; H, 4.47; N, 4.78 Found: C, 63.37; H, 4.36; N, 4.67.

1-[(2,3,5-Tri-*O*-benzoyl- β -D-ribofuranosyloxy)methyl]thymine (6b). Prepared according to method B (2.22 mmol) by reacting **4** (1.0 g, 1.87 mmol) and **5b** (0.6 g, 2.22 mmol) in CHCl_3 (40 mL) at reflux for 4 h to isolate the title compound as a white crystalline solid (0.88 g, 78.6% yield). mp 82–84°C; $[\alpha]_D$ 41.0 (c 1.0, CHCl_3); UV λ_{max} (MeOH) nm: 266; IR (KBr) ν_{max} 3176, 2970, 1721, 1684, 1369, 1307, 1269, 1092, 1062 and 1031 cm^{-1} ; ^1H NMR (200 MHz; CDCl_3) δ 1.90 (3H, s, CH_3), 4.50 (1H, dd, $J = 14.0, 6.5$ Hz, H5'), 4.60–4.80 (2H, m, H4', H5''), 5.10, 5.36 (2H, AB type quartet, $J = 10.0$ Hz, OCH_2N), 5.50 (1H, s, H1'), 5.70 (1H, d, $J = 5.0$ Hz, H2'), 5.80 (1H, dd, $J = 4.0$ Hz, H3'), 6.98 (1H, s, H6), 7.20–8.20 (15H, m, aromatic), 8.50 (1H, br s, NH); ^{13}C NMR (50 MHz; CDCl_3) δ 12.2 (CH_3), 64.6 (C5'), 74.5 (C4'), 76.0 (C3'), 78.0 (C2'), 80.0 (OCH_2N), 104.7 (C1'), 111.5 (C5), 127–135 (aromatic), 151.0 (C=O, C2) 164.0 (C=O, C4) 164.8, 165.0 and 165.8 (C=O, ester); FAB-MS m/z : 601 $[\text{M}^+ + \text{H}]$; Anal. calcd for $\text{C}_{32}\text{H}_{28}\text{O}_{18}\text{N}_2$: C, 63.99; H, 4.70; N, 4.66. Found: C, 64.17; H, 4.62; N, 4.59.

1-[(2,3,5-Tri-*O*-benzoyl- β -D-ribofuranosyloxy)methyl]cytosine (6c). Prepared according to method A (6.74 mmol) by reacting **4** (3.0 g, 5.61 mmol) and **5a** (1.71 g, 6.74 mmol) in CHCl_3 (30 mL) at room temperature for 6 h to isolate after chromatographic separation (ethyl acetate:chloroform, 2:1) **7c** (1.47 g, 47.4% yield) as a crystalline solid mp 180–82°C (lit.¹³ mp 182–83°C) and the title compound **6c** (0.96 g, 29.5% yield) as a white crystalline solid. mp 178–181°C; $[\alpha]_D$ 29.0 (c 1.0, CHCl_3); UV λ_{max} (MeOH) nm: 271; IR (KBr) ν_{max} 3336, 3200, 1728, 1664, 1616, 1488, 1370, 1264, 1088 and 1040 cm^{-1} ; ^1H NMR (200 MHz; CDCl_3) δ 4.50 (1H, dd, $J = 13.0, 5.0$ Hz, H5'), 4.60–4.80 (2H, m, H4', H5''), 5.15, 5.40 (2H, AB type quartet, $J = 10.0$ Hz, OCH_2N), 5.60 (1H, s, H1'), 5.70 (d, $J = 5.0$ Hz, H2'), 5.85 (1H, dd, $J = 3.0$ Hz, H3'), 5.95 (1H, d, $J = 7.5$ Hz, H5), 7.15–8.15 (16H, m, H6, aromatic); ^{13}C NMR (50 MHz; CDCl_3) δ 64.7 (C5'), 72.1 (C4'), 75.5 (C2'), 76.5 (C3'), 79.5 (OCH_2N), 104.2 (C1'), 128–135 (aromatic), 144.6 (C6), 156.1 (C4), 165.1 (C=O, C2) 165.4, 166.0, 166.1 (C=O, ester); FAB-MS m/z : 586 $[\text{M}^+ + \text{H}]$; Anal. calcd for $\text{C}_{31}\text{H}_{27}\text{O}_9\text{N}_3$: C, 63.58; H, 4.65; N, 7.18. Found: C, 63.41; H, 4.59; N, 7.12.

***N*⁴-Benzoyl-1-[(2,3,5-tri-*O*-benzoyl- β -D-ribofuranosyloxy)methyl]cytosine (6d).** Prepared according to method B (1.11 mmol) by reacting **4** (0.5 g, 0.93 mmol) and **5d** (0.4 g, 1.11 mmol) in CHCl_3 (20 mL) at reflux temperature for 4 h to isolate after

chromatographic separation (ethylacetate:chloroform, 2:1) **7d** (0.1 g, 17.0% yield) as a crystalline solid mp 205–7°C (lit.¹³ mp 206.5–208°C) and the title compound **6d** (0.33 g, 52.0% yield) as a white crystalline solid. mp 126–128°C; $[\alpha]_D$ 9.0 (c 1.0, CHCl₃); UV λ_{\max} (MeCN) nm: 258; IR (KBr) ν_{\max} 3062, 2915, 1723, 1662, 1604, 1530, 1454, 1307, 1270, 1100, 1046, 970, 815 and 692 cm⁻¹; ¹H NMR (200 MHz; CDCl₃) δ 4.50 (1H, dd, J = 13.0, 5.0 Hz, H5'), 4.55–4.75 (2H, m, H4',H5''), 5.20, 5.50 (2H, AB type quartet, J = 10.0 Hz, OCH₂N), 5.60 (1H, s, H1'), 5.65 (1H, d, J = 5.0 Hz, H2'), 5.70–5.90 (1H, m, H3'), 7.20–8.15 (17H, m, H5,H6,aromatic); FAB-MS m/z : 690 [M^+ + H]; Anal. calcd for C₃₈H₃₁O₁₀N₃:C, 66.18; H, 4.53; N, 6.09. Found: C, 66.31; H, 4.48; N, 6.02.

***N*⁶-Benzoyl-9-[(2,3,5-tri-*O*-benzoyl- β -D-ribofuranosyloxy)methyl]adenine (**6e**).**

Prepared according to method B (3.7 mmol) by reacting **4** (1.0 g, 1.87mmol) and **5a** (0.86 g, 2.24 mmol) in MeCN (40 mL) at room temperature for 16 h to isolate after chromatographic separation (ethyl acetate:chloroform, 2:1) **7e** (0.44 g, 34.9% yield) as a crystalline solid mp 89–91°C (lit.¹³ mp 88–92°C) and the title compound **6e** (0.6 g, 45.4% yield) as a yellowish solid. mp 113–116°C; $[\alpha]_D$ 7.0 (c 1, CHCl₃); UV λ_{\max} (MeCN) nm: 277; IR (KBr) ν_{\max} 3323, 3085, 1723, 1616, 1508, 1446, 1323, 1261, 1062, 1015 and 708 cm⁻¹; ¹H NMR (200 MHz; CDCl₃) δ 4.50 (1H, dd, J = 14.0, 5.0 Hz, H5'), 4.65–4.90 (2H, m, H4',H5''), 5.50 (1H, s, H1'), 5.60–6.00 (4H, m, OCH₂N,H2',H3'), 7.20–8.20 (21H, m, H8, aromatic), 8.80 (1H,s, H2), 9.00 (1H, br s, NH); ¹³C NMR (50 MHz; CDCl₃) δ 45.2 (C5'), 64.3 (C4'), 75.3 (C2'), 81.1 (OCH₂N), 104.0 (C1'), 122.1 (C5), 125–135 (aromatic) 143.0 (C8), 149.7 (C4), 152.0 (C2), 153.1 (C6), 164.8, 165.0, 165.3, 166.0 (C=O,ester); FAB-MS m/z : 714 [M^+ + H]; Anal. calcd for C₃₉H₃₁O₉N₅:C, 65.68; H, 4.37; N, 9.82. Found: C, 63.81; H, 4.21; N, 9.72.

***N*²-Acetyl-9-[(2,3,5-tri-*O*-benzoyl- β -D-ribofuranosyloxy)methyl]guanine (**6f**)**

***N*²-Acetyl-7-[(2,3,5-tri-*O*-benzoyl- β -D-ribofuranosyloxy)methyl]guanine (**6g**).** Prepared according to method B (2.24 mmol) by reacting **4** (1.0 g, 1.87 mmol) and **5f** (0.91 g, 2.24 mmol) in 1,2-dichloroethane (40 mL) at reflux temperature for 2 h to isolate after chromatographic separation (ethyl acetate:chloroform, 3:1) the title compound **6f** (0.38 g, 29.7% yield) as a white crystalline solid. mp 125–127°C; $[\alpha]_D$ 42.0 (c 1, CHCl₃); UV λ_{\max} (MeCN) nm: 281; IR (KBr) ν_{\max} 3170, 3046, 2923, 1730, 1677, 1600, 1554, 1430, 1338, 1261, 1077, 1000 and 692 cm⁻¹; ¹H NMR (200 MHz; CDCl₃) δ 2.38 (3H, s, Ac), 4.60–4.85 (3H,m, H4',H5',H5''), 5.50 (1H,s, H1'), 5.45–5.65 (2H, AB type quartet, J = 10.0 Hz, OCH₂N), 5.60–5.80 (2H, m, H2',H3'), 7.15–8.00 (15H, m, aromatic), 10.42 (1H, br s, NH), 12.00 (1H, br s, NH); FAB-MS m/z : 668 [M^+ + H]; Anal. calcd for C₃₄H₂₉O₁₀N₅:C, 61.16; H, 4.38; N, 10.4. Found: C, 61.28; H, 4.27; N, 10.32.; followed by (**6g**) (0.34 g, 27% yield) as a white crystalline solid. mp 225–228°C; $[\alpha]_D$ – 30.0 (c 1, CHCl₃); UV λ_{\max} (MeCN) nm: 266; IR (KBr) ν_{\max} 3300, 2930, 2861, 1715, 1685, 1616, 1385, 1315, 1261, 1092, 1046, 1030 and 692 cm⁻¹; ¹H NMR (200 MHz; CDCl₃) δ 2.20 (3H, s, Ac), 4.20–4.80 (3H, m, H4',H5',H5''), 5.65 (1H, s, H1'), 5.70–6.08 (4H, m, OCH₂N, H2',H3'), 7.20–8.20 (15H, m, aromatic), 11.50 (1H, br s, NH), 12.20 (1H,br s, NH); FAB-MS m/z : 668 [M^+ + H]; Anal. calcd for C₃₄H₂₉O₁₀N₅:C, 66.16; H, 4.38; N, 10.49. Found: C, 66.01; H, 4.29; N, 10.33.

1-[(β -D-Ribofuranosyloxy)methyl]uracil (8a). To a solution of **6a** (0.9g, 1.53 mmol) in methanol (18 mL) was added a catalytic amount of NaHCO₃ (0.1 g) and refluxed for 3 h. After completion of the reaction the reaction mixture was neutralized with IR 120 H⁺ resin, filtered, washed with methanol (10 mL) and filtrate was evaporated to a residue. The residue was dissolved in water (25 mL) washed with chloroform (25 mL), the water phase was concentrated to isolate the title compound as a white solid in 93% yield (0.39 g), mp 113–115°C; [α]_D 144.0 (c 1.0, H₂O); UV λ_{\max} (H₂O) nm: 260, (0.1N, NaOH) 261; IR (KBr) ν_{\max} 3370, 3046, 2830, 2315, 1685, 1446, 1262, 1054, 953 and 815 cm⁻¹; ¹H NMR (400 MHz; D₂O) δ 3.60 (1H, dd, J = 10.0, 5.5 Hz, H5'), 3.80 (1H, dd, J = 4.0 Hz, H5''), 4.05 (1H, m, H3'), 4.12 (1H, d, J = 5.5 Hz, H2'), 5.22 (1H, s, H1'), 5.27, 5.40 (2H, AB type quartet, J = 11.0 Hz, OCH₂N), 5.90 (1H, d, J = 5.5 Hz, H5), 7.80 (1H, d, H6); ¹³C NMR (50 MHz; D₂O) δ 63.0 (C5'), 71.0 (C4'), 75.0 (C3'), 75.5 (C2'), 83.5 (OCH₂N), 102.5 (C5), 106.0 (C1'), 146.5 (C6), 152.25 (C=O, C2), 166.5 (C=O, C4); FAB-MS m/z : 275 [M⁺ + H]; Anal. calcd for C₁₀H₁₄O₇N₂:C, 43.80; H, 5.15; N, 10.22. Found: C, 43.67; H, 5.11; N, 10.25.

1-[(β -D-Ribofuranosyloxy)methyl]thymine (8b). To a solution of **6b** (0.7g, 1.16 mmol) in methanol (14 mL) was added a catalytic amount of NaHCO₃ (0.08 g) and refluxed for 3 h. to isolate by the work up described for **8a** the title compound as a white crystalline solid in 98.5% yield (0.33 g). mp 188–190°C; [α]_D -22.0 (c 1.0, MeOH); UV λ_{\max} (MeOH) nm: 265, (0.1N NaOH) 266; IR (Neat) ν_{\max} 3400, 2953, 1693, 1677, 1362, 1330, 1260, 1076 and 1030 cm⁻¹; ¹H NMR (200 MHz; D₂O) δ 1.90 (3H, s, CH₃), 3.60 (1H, dd, J = 14.0, 6.5 Hz, H5'), 3.80 (1H, dd, J = 4.0 Hz, H5''), 3.90–4.30 (2H, m, H3', H4'), 5.20 (1H, s, H1'), 5.25, 5.35 (2H, AB type quartet, J = 10.0 Hz, OCH₂N), 7.60 (1H, s, H6), 8.00 (1H, br s, NH); ¹³C NMR (50 MHz; D₂O) δ 10.7 (CH₃), 62.2 (C5'), 70.1 (C4'), 74.0 (C3'), 74.4 (C2'), 82.6 (OCH₂N), 105.2 (C1'), 110.6 (C5), 141.3 (C6), 151.5 (C=O, C2), 166.1 (C=O, C4); FAB-MS m/z : 311 [M⁺ + Na]; Anal. calcd for C₁₁H₁₆O₇N₂:C, 45.83, H, 5.60, N, 9.2. Found: C, 45.91; H, 5.52; N, 9.13.

1-[(β -D-Ribofuranosyloxy)methyl]cytosine (8c). To a solution of **6c** (0.9g, 1.5 mmol) in methanol (18 mL) was added a catalytic amount of NaHCO₃ (0.1 g) and refluxed for 3 h. to isolate by the work up described for **8a** the title compound as a white crystalline solid in 75 % yield (0.31 g) as a white solid. mp 146°C; [α]_D 16.0 (c 1, MeOH); UV λ_{\max} (MeOH) nm: 268, (0.1N NaOH) 270; IR (Neat) ν_{\max} 3446, 1662, 1500, 1384, 1200 and 731 cm⁻¹; ¹H NMR (200 MHz; D₂O) δ 3.60 (1H, dd, J = 13.0, 5.0 Hz, H5'), 3.80 (1H, dd, J = 3.0 Hz, H5''), 3.90–4.30 (3H, m, H2', H3', H4'), 5.20 (1H, s, H1'), 5.20, 5.40 (1H, AB type quartet, J = 10.0 Hz, OCH₂N), 6.15 (1H, d, J = 7.5 Hz, H5), 7.70 (1H, d, H6); ¹³C NMR (50 MHz; D₂O) δ 62.1 (C5'), 70.1 (C4'), 74.0 (C3'), 76.0 (C2'), 82.5 (OCH₂N), 105.2 (C1'), 146.0 (C6), 156.6 (C4), 165.5 (C=O, C2); FAB-MS m/z : 274 [M⁺ + H]; Anal. calcd for C₁₀H₁₅O₆N₂:C, 43.95; H, 5.53; N, 15.38. Found: C, 43.81; H, 5.45; N, 15.22.

9-[(β -D-Ribofuranosyloxy)methyl]adenine (8e). To a solution of **6e** (0.4g, 0.56 mmol) in methanol (8 mL) was added a catalytic amount of NaHCO₃ (0.05 g) and refluxed for 5 h. to isolate by the work up described for **8a** the title compound as a white crystalline solid in 83.2% yield (0.14 g). mp 155–158°C; [α]_D -34.0 (c 1, DMSO); UV λ_{\max} (H₂O) nm: 259; IR (KBr) ν_{\max} 3308, 1670, 1685, 1600, 140.8, 1370,

1285, 1123, 1062, 1023, 962, 800 and 722 cm^{-1} ; ^1H NMR (200 MHz; DMSO- d_6) δ 3.20–4.00 (6H, m, H2', H3', H4', H5', H5'', OH), 4.75 (1H, br s, OH), 4.90 (1H, s, H1'), 5.10 (1H, br s, OH), 5.55, 5.70 (2H, AB type quartet, $J = 10.0$ Hz, OCH_2N), 7.25 (2H, br s, NH_2), 8.20 (1H, s, H8), 8.25 (1H, s, H2); ^{13}C NMR (50 MHz; DMSO- d_6) δ 62.6 (C5'), 68.6 (C4'), 70.6 (C3'), 74.5 (C2'), 84.1 (OCH_2N), 105.1 (C1'), 118.6 (C5), 141.5 (C8), 149.6 (C4), 153.0 (C2), 156.0 (C6); FAB-MS m/z : 298 [$\text{M}^+ + \text{H}$]; Anal. calcd for $\text{C}_{11}\text{H}_{15}\text{O}_5\text{N}_5$: C, 44.44; H, 5.09; N, 23.56. Found: C, 44.51; H, 5.01; N, 23.44.

9-[(β -D-Ribofuranosyloxy)methyl]guanine (8f). To a solution of **6f** (0.3g, 0.44 mmol) in methanol (6 mL) was added a catalytic amount of NaHCO_3 (0.05 g) and refluxed for 3 h. to isolate by the work up described for **8a** the title compound as a white crystalline solid in 78.5% yield (0.11 g). mp 260–262°C; $[\alpha]_D -4.0$ (c 0.5, DMSO); UV λ_{max} (H_2O) nm: 252; IR (KBr) ν_{max} 3353, 3200, 2970, 2892, 2762, 1692, 1646, 1600, 1523, 1477, 1168, 1015, 984, 790, 692 and 570 cm^{-1} ; ^1H NMR (300 MHz; DMSO- d_6) δ 3.25–3.60 (2H, m, H5', H5''), 3.64 (1H, s, H2'), 3.65–4.00 (2H, m, H3', H4'), 4.65 (1H, s, OH), 4.88 (1H, s, OH), 4.90 (1H, s, H1'), 5.14 (1H, s, OH), 5.35, 5.45 (2H, AB type quartet, $J = 10.0$ Hz, OCH_2N), 6.55 (2H, br s, NH_2), 7.75 (1H, s, H8), 10.70 (1H, br s, NH); ^{13}C NMR (50 MHz; DMSO- d_6) δ 62.5 (C5'), 68.1 (C4'), 70.5 (C3'), 74.3 (C2'), 84.0 (OCH_2N), 104.7 (C1'), 116.4 (C5), 137.7 (C8), 151.2 (C4), 153.9 (C2), 156.7 (C6); FAB-MS m/z : 314 [$\text{M}^+ + \text{H}$]; Anal. calcd for $\text{C}_{11}\text{H}_{15}\text{O}_6\text{N}_5$: C, 42.17; H, 4.83; N, 22.36. Found: C, 42.26; H, 4.72; N, 22.2.

7-[(β -D-Ribofuranosyloxy)methyl]guanine (8g). To a solution of **6g** (0.3g, 0.44 mmol) in methanol (6 mL) was added a catalytic amount of NaHCO_3 (0.05 g) and refluxed for 5 h. to isolate by the work up procedure described for **8a** the title compound as a white crystalline solid in 93% yield (0.13 g). mp 264°C (decomposed); $[\alpha]_D 24.0$ (c 0.5, DMSO); UV λ_{max} (H_2O) nm: 285; IR (KBr) ν_{max} 3315, 3154, 2915, 1661, 1538, 1454, 1370, 1210, 1092 and 1030 cm^{-1} ; ^1H NMR (500 MHz; DMSO- d_6) δ 3.20–3.60 (2H, m, H5', H5''), 3.70 (1H, s, H2'), 3.75–3.95 (2H, m, H3', H4'), 4.60 (1H, s, OH), 4.80 (1H, s, OH), 4.90 (1H, s, H1'), 5.00 (1H, s, OH), 5.60, 5.65 (2H, AB type quartet, $J = 10.0$ Hz, OCH_2N), 6.20 (2H, br s, NH_2), 8.00 (1H, s, H8), 10.90 (1H, br s, NH); ^{13}C NMR (75 MHz; DMSO- d_6) δ 63.4 (C5'), 71.4 (C4'), 72.3 (C3'), 75.3 (C2'), 84.8 (OCH_2N), 105.7 (C1'), 106.4 (C5), 145.0 (C8), 154.0 (C2), 155.3 (C6), 161.0 (C4); FAB-MS m/z : 314 [$\text{M}^+ + \text{H}$]; Anal. calcd for $\text{C}_{11}\text{H}_{15}\text{O}_6\text{N}_5$: C, 42.17; H, 4.83; N, 22.36. Found: C, 42.24; H, 4.71; N, 22.19.

ACKNOWLEDGMENT

MSK thanks Council for Scientific and Industrial Research, New Delhi for the financial assistance in the form of a Senior Research Fellowship.

REFERENCES

1. Niedballa, U.; Vorbruggen, H. A general synthesis of N-glycosides. On the mechanism of the stannic chloride catalyzed silyl Hilbert–Johnson reaction. *J. Org. Chem.* **1976**, *41*, 2084–2086.

2. Niedballa, U.; Vorbruggen, H. A general synthesis of N-glycosides. I. Synthesis of pyrimidine nucleosides. *J. Org. Chem.* **1974**, *39*, 3654–3660.
3. Niedballa, U.; Vorbruggen, H. A general synthesis of N-glycosides. II. Synthesis of 6-methyluridines. *J. Org. Chem.* **1974**, *39*, 3660–3663.
4. Niedballa, U.; Vorbruggen, H. A general synthesis of N-glycosides. III. A simple synthesis of pyrimidine disaccharide nucleosides. *J. Org. Chem.* **1974**, *39*, 3664–3667.
5. Niedballa, U.; Vorbruggen, H. A general synthesis of N-glycosides. IV. Synthesis of hydroxy and mercapto N-heterocycles. *J. Org. Chem.* **1974**, *39*, 3668–3671.
6. Niedballa, U.; Vorbruggen, H. A general synthesis of N-glycosides. V. Synthesis of 5-azacytidines. *J. Org. Chem.* **1974**, *39*, 3672–3674.
7. Vorbruggen, H.; Gerhard, H. On mechanism of nucleoside synthesis. *Chem. Ber.* **1981**, *114*, 1256–1268.
8. Hilbert, G.E.; Johnson, T.B. Researches on pyrimidines. CXVII. A method for the synthesis of nucleosides. *J. Am. Chem. Soc.* **1930**, *52*, 4489–4494.
9. Anderson, C.B.; Friedrich, E.C.; Winstien, S. The cis-cyclohexene acetoxonium ion. 2-Methyl-cis-4,5-tetramethylene-1,3-dioxolenium tetrafluoroborate. *Tetrahedron Lett.* **1963**, 2037–2044. Structure of 1,2-acyloxonium salts.
10. Hart, H.; Tomalia, D.A. Alkoxy carbonium ions. NMR examination of 2-alkyl-1,3-dioxolenium cations. *Tetrahedron Lett.* **1966**, 3383–3388.
11. Paulsen, H.; Meyborg, M. Darstellung von acyloxonium-ionen einwirkung von trifluormethanesulfonsäure auf diol-und triolester. *Chem. Ber.* **1975**, *108*, 3176–3189.
12. Sarybaeva, R.I.; Afanas'ev, V.A.; Zaikov, G.E.; Schelokhova, L.S. The application of Lewis acids in carbohydrate chemistry. *Russ. Chem. Rev.* **1977**, *46*, 722–730.
13. Perst, H. *Oxonium Ions in Organic Chemistry*; Verlag Chemie–Academic Press: Weinheim, NY, 1971.
14. Watanabe, K.A.; Hollenberg, D.H.; Fox, J.J. Nucleosides. LXXXV. Mechanisms of nucleoside synthesis by condensation reactions. *J. Carbohydr., Nucleosides, Nucleotides* **1974**, *1*, 1–37.
15. Wilson, L.J.; Hager, M.W.; El-Kattan, Y.A.; Liotta, D.C. Nitrogen glycosylation reactions involving pyrimidine and purine nucleoside bases with furanoid sugars. *Synthesis* **1995**, 1445–1479.
16. Vorbruggen, H.; Ruh-pohlenz, C. *Organic Reactions*; Paquett, L.A., Ed.; John-Wiley & Sons Inc.: New York, 2000; Vol. 55, 1–630.
17. Davis, B.G. Recent developments in oligosaccharide synthesis. *J. Chem. Soc., Perkin. Trans.*, **1** **2000**, 2137–2160.
18. Fraser-Reid, B.; Zufan-Wu, C.; Andrews, W.; Skowronski, E. Torsional effects in glycoside reactivity. Saccharide couplings mediated by acetal protecting groups. *J. Am. Chem. Soc.* **1991**, *113*, 1434–1435.
19. Ratcliffe, A.J.; Mootoo, D.R.; Andrews, C.W.; Fraser-Reid, B. Concerning the antiperiplanar lone pair hypothesis. Oxidative hydrolysis of conformationally restrained 4-pentenyl glycosides. *J. Am. Chem. Soc.* **1989**, *111*, 7661–7662.
20. Deslongchamps, P. *Stereoelectronic Effects in Organic Chemistry*; Pergamon press: New York, 1983; 30–35.
21. Ness, R.K.; Diehl, H.W.; Fletcher, H.G., Jr. New benzoyl derivatives of D-ribofuranose and aldehydo-D-ribose. The preparation of crystalline 2,3,5-tri-O-benzoyl- β -D-ribose from D-ribose. *J. Am. Chem. Soc.* **1954**, *76*, 763–767.



22. Barker, R.; Fletcher, H.G. 2,3,5-Tri-*O*-benzyl-D-ribosyl and L-arabinosyl bromides. *J. Org. Chem.* **1961**, *26*, 4605–4609.
23. Mereyala, H.B.; Gurralla, S.R. A highly diastereoselective, practical synthesis of allyl, propargyl 2,3,4,6-tetra-*O*-acetyl- β -D-glucopyranosides and allyl, propargyl heptaacetyl- β -D-lactosides. *Carbohydr. Res.* **1998**, *307*, 351–354.
24. Mereyala, H.B.; Gurralla, S.R. Design, development and utility of glycosyl donors bearing an acetoxymethoxy leaving group. *Chem. Lett.* **1998**, 863–864.
25. Nishimura, T.; Iwai, I. Studies on synthetic nucleosides. I. Trimethylsilyl derivatives of pyrimidines and purines. *Chem. Pharm. Bull.* **1964**, *12* (3), 352–356.
26. Kelley, J.L.; Krochmal, M.P.; Schaffer, H.J. Pyrimidine acyclic nucleosides. 5-Substituted 1-[(2-aminoethoxy) methyl] uracils as candidate antivirals. *J. Med. Chem.* **1981**, *24*, 472–478.
27. Baker, B.R.; Kawazu, M.; Santi, D.V.; Schwan, J.J. Irreversible enzyme inhibitors. LXXVII. Inhibitors of thymidine phosphorylase. III. Hydrophobic bonding by 1-substituted uracils containing additional substituents at the 5 and 6 positions. *J. Med. Chem.* **1967**, *10*, 304–308.
28. Shugar, D.; Fox, J.J. Spectrophotometric studies of nucleic acid derivatives and related compounds as a function of P^H . *Biochim. Biophys. Acta* **1952**, *9*, 199–218.
29. Shimomura, N.; Matsulani, T.; Mukaiyama, T. Stereoselective synthesis of β -D-ribonucleosides catalyzed by the combined use of silver salts and diphenyltin sulfide or Lawesson's reagent. *Bull. Chem. Soc. Jpn.* **1994**, *67*, 3100–3106.
30. Vorbruggen, H.; Krolkiewicz, K.; Bennua, B. Nucleoside synthesis. XXII. Nucleoside synthesis with trimethylsilyltriflate and perchlorate as catalysts. *Chem. Ber.* **1981**, *114*, 1234–1255.
31. Horst, D.K. *An Introduction to the Chemistry and Biochemistry of Pyrimidines, Purines and Pteridines*; John Wiley & Sons: Chichester, 1979; 15–41.
32. Brown, D.J. *The Pyrimidines*; Wiley-Interscience: New York, 1962; 464–495.
33. Brown, D.M.; Todd, A.; Varadarajan, S. The structures of some acylcytosines. *J. Chem. Soc.* **1956**, 2384–2387.
34. Baizer, M.M.; Clark, J.R.; Michael, D.; Loter, A. A new synthesis of kinetin and its analogs. *J. Org. Chem.* **1956**, *21*, 1276–1277.
35. Miyaki, M.; Shimizu, B. N–N Alkyl and glycosyl migration of purines and pyrimidines. III. N–N Alkyl and glycosyl migration of purine derivatives. *Chem. Pharm. Bull.* **1970**, *18*, 1446–1456.
36. Schaeffer, H.J.; Beauchamp, L.; de Miranda, P.; Elion, G.B.; Bauer, D.J.; Collins, P. 9-(2-hydroxyethoxymethyl) guanine activity against viruses of the herpes group. *Nature (London)* **1978**, *272*, 583–585.
37. Elion, G.B.; Furman, P.A.; Fyfe, J.A.; de Miranda, P.; Beauchamp, L.; Schaeffer, H.J. Selectivity of action of an antiherpetic agents, 9-(2-hydroxyethoxymethyl) guanine. *Proc. Natl. Acad. Sci. U. S. A.* **1977**, *74*, 5716–5720.
38. Martin, J.C.; Dvorak, C.A.; Smee, D.F.; Julien, P.H.; Mathews, T.R.; Verheyden, J.P.H. 9-[(1,3-Dihydroxy-2-propoxy) methyl] guanine. A new potent and selective antiherpes agent. *J. Med. Chem.* **1983**, *26*, 759–761.
39. Field, E.K.; Davies, M.E.; DeWitt, C.; Perry, H.C.; Liou, R.; Germershausen, J.; Karkas, J.D.; Ashton, W.T.; Johnston, D.B.R.; Tolman, R.L. 9-[(2-Hydroxymethyl) ethoxy] methyl] guanine. A selective inhibitor of herpes group viruses replication. *Proc. Natl. Acad. Sci. U. S. A.* **1983**, *80*, 4139–4143.



40. Harnden, M.R.; Jarvest, R.L.; Bacon, T.H.; Boyd, M.R. Synthesis and antiviral activity of 9-[-4-hydroxy-3-(hydroxymethyl) but-1-yl] purines. *J. Med. Chem.* **1987**, *30*, 1636–1642.
41. Zou, R.; Robins, J. High yield regioselective synthesis of 9-glycosyl guanine nucleosides and analogues via coupling with 2-N-acetyl-6-O-diphenyl carbamoyl guanine. *Can. J. Chem.* **1987**, *65*, 1436–1437.
42. Kjellberg, J.; Johansson, N.G. Characterization of N⁷ and N⁹ alkylated purine analogues by ¹H and ¹³C NMR. *Tetrahedron* **1986**, *42*, 6541–6544.
43. Garner, P.; Ramakanth, S. A regiocontrolled synthesis of N⁷- and N⁹-guanine nucleosides. *J. Org. Chem.* **1988**, *53*, 1294–1298.
44. Robins, M.J.; Zou, R.; Guo, Z.; Wnuk, S.F. Nucleic acid related compounds. 93. A solution for the historic problem of regioselective sugar-base coupling to produce 9-glycosylguanines or 7-glycosylguanines. *J. Org. Chem.* **1996**, *61*, 9207–9212.
45. Golanaiewicz, D.; Ostrowski, T.; Leonard, P.; Seela, F. The thermal N⁹\N⁷ isomerization of N²-acylated 2' deoxyguanosine derivatives in the melt and in the solution. *Helv. Chem. Acta.* **2002**, *85*, 388–398.
46. Ho, L.T. The hard soft acids bases (HSAB) principle and organic chemistry. *Chem. Rev.* **1975**, *75*, 1–20.
47. Olah, G.H. *Friedel-Crafts and Related Reactions*; Wiley: New York, 1964; Vol. 3.
48. Bright, J.R.; Fernelius, W.C. Association of borontrifluoride addition compounds with amines in non-polar solvents. *J. Am. Chem. Soc.* **1943**, *65*, 735–736.
49. Wolstenholme, G.E.W.; O'Connor, C.M. *Ciba Foundation Symposium on Chemistry and Biology of Purines*; J&A Churchill. Ltd.: London, 1957; 1–317, 104. Gloucester Place, W1.

Received May 9, 2003

Accepted December 31, 2003



Request Permission or Order Reprints Instantly!

Interested in copying and sharing this article? In most cases, U.S. Copyright Law requires that you get permission from the article's rightsholder before using copyrighted content.

All information and materials found in this article, including but not limited to text, trademarks, patents, logos, graphics and images (the "Materials"), are the copyrighted works and other forms of intellectual property of Marcel Dekker, Inc., or its licensors. All rights not expressly granted are reserved.

Get permission to lawfully reproduce and distribute the Materials or order reprints quickly and painlessly. Simply click on the "Request Permission/Order Reprints" link below and follow the instructions. Visit the [U.S. Copyright Office](#) for information on Fair Use limitations of U.S. copyright law. Please refer to The Association of American Publishers' (AAP) website for guidelines on [Fair Use in the Classroom](#).

The Materials are for your personal use only and cannot be reformatted, reposted, resold or distributed by electronic means or otherwise without permission from Marcel Dekker, Inc. Marcel Dekker, Inc. grants you the limited right to display the Materials only on your personal computer or personal wireless device, and to copy and download single copies of such Materials provided that any copyright, trademark or other notice appearing on such Materials is also retained by, displayed, copied or downloaded as part of the Materials and is not removed or obscured, and provided you do not edit, modify, alter or enhance the Materials. Please refer to our [Website User Agreement](#) for more details.

Request Permission/Order Reprints

Reprints of this article can also be ordered at

<http://www.dekker.com/servlet/product/DOI/101081NCN120030722>